NCT00095810已完成4 期
An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease
Otsuka Pharmaceutical Development & Commercialization, Inc.1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2003年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Tolerability
研究概览
简要总结
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary diagnosis of idiopathic Parkinson's disease.
- •Psychosis related to Parkinson's disease.
排除标准
- •Psychosis present prior to diagnosis of Parkinson's disease.
研究组 & 干预措施
A
Experimental
干预措施: aripiprazole (Drug)
结局指标
主要结局
Tolerability
次要结局
- Safety Assessments
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
An Open-Label Trial of Aripiprazole in Autism Spectrum DisordersAsperger's DisorderAutismPervasive Developmental DisorderNCT00308074Cambridge Health Alliance14
已完成
3 期
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric PracticesSchizophreniaNCT00237939Otsuka Pharmaceutical Development & Commercialization, Inc.1,200
已完成
3 期
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric PracticesSchizophrenia and Schizoaffective DisorderNCT00292409Otsuka Pharmaceutical Development & Commercialization, Inc.400
已完成
3 期
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With SchizophreniaSchizophreniaNCT01942148Otsuka Pharmaceutical Co., Ltd.68
已完成
3 期
Oral Aripiprazole Open-Label Rollover StudySchizophreniaNCT01001702Otsuka Pharmaceutical Development & Commercialization, Inc.85